NovaBay Pharmaceuticals, Inc. (NBY)
- Previous Close
0.0770 - Open
0.0780 - Bid 0.0770 x 1200
- Ask 0.0778 x 1200
- Day's Range
0.0720 - 0.0784 - 52 Week Range
0.0700 - 1.4200 - Volume
595,882 - Avg. Volume
3,627,353 - Market Cap (intraday)
2.791M - Beta (5Y Monthly) 2.01
- PE Ratio (TTM)
-- - EPS (TTM)
-3.9600 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.60
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
novabay.comRecent News: NBY
Performance Overview: NBY
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NBY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NBY
Valuation Measures
Market Cap
2.78M
Enterprise Value
4.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.02
Price/Book (mrq)
2.04
Enterprise Value/Revenue
0.29
Enterprise Value/EBITDA
-0.90
Financial Highlights
Profitability and Income Statement
Profit Margin
-65.46%
Return on Assets (ttm)
-24.59%
Return on Equity (ttm)
-139.02%
Revenue (ttm)
14.73M
Net Income Avi to Common (ttm)
-16.7M
Diluted EPS (ttm)
-3.9600
Balance Sheet and Cash Flow
Total Cash (mrq)
3.13M
Total Debt/Equity (mrq)
82.68%
Levered Free Cash Flow (ttm)
-173.88k